DK168911B1 - Anvendelse af azoniaspironortropanolestere til fremstilling af et præparat til behandling af astma og bronchospasmer - Google Patents
Anvendelse af azoniaspironortropanolestere til fremstilling af et præparat til behandling af astma og bronchospasmer Download PDFInfo
- Publication number
- DK168911B1 DK168911B1 DK626086A DK626086A DK168911B1 DK 168911 B1 DK168911 B1 DK 168911B1 DK 626086 A DK626086 A DK 626086A DK 626086 A DK626086 A DK 626086A DK 168911 B1 DK168911 B1 DK 168911B1
- Authority
- DK
- Denmark
- Prior art keywords
- chloride
- asthma
- esters
- treatment
- aerosol
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 title claims description 7
- 150000002148 esters Chemical class 0.000 title claims description 6
- 208000014181 Bronchial disease Diseases 0.000 title claims description 5
- 208000009079 Bronchial Spasm Diseases 0.000 title claims description 4
- 206010006482 Bronchospasm Diseases 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 239000004135 Bone phosphate Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 229960001530 trospium chloride Drugs 0.000 description 10
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- -1 halide ion Chemical class 0.000 description 4
- 229960001317 isoprenaline Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000434 field desorption mass spectrometry Methods 0.000 description 3
- 230000002445 parasympatholytic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001813 broncholytic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001975 sympathomimetic effect Effects 0.000 description 2
- 229940064707 sympathomimetics Drugs 0.000 description 2
- YYMCYJLIYNNOMK-MEKDEQNOSA-N (1r,5s)-8-azabicyclo[3.2.1]octan-3-ol Chemical compound C1C(O)C[C@@H]2CC[C@H]1N2 YYMCYJLIYNNOMK-MEKDEQNOSA-N 0.000 description 1
- VPENPAROZCZHAF-UHFFFAOYSA-M (2-acetyloxy-2-methoxyethyl)-trimethylazanium chloride Chemical compound [Cl-].COC(C[N+](C)(C)C)OC(C)=O VPENPAROZCZHAF-UHFFFAOYSA-M 0.000 description 1
- ZXUJWPHOPHHZLR-UHFFFAOYSA-N 1,1,1-trichloro-2-fluoroethane Chemical compound FCC(Cl)(Cl)Cl ZXUJWPHOPHHZLR-UHFFFAOYSA-N 0.000 description 1
- KJDRSWPQXHESDQ-UHFFFAOYSA-N 1,4-dichlorobutane Chemical compound ClCCCCCl KJDRSWPQXHESDQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- YYMCYJLIYNNOMK-UHFFFAOYSA-N N-normethyltropine Natural products C1C(O)CC2CCC1N2 YYMCYJLIYNNOMK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 229960001491 trospium Drugs 0.000 description 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853546165 DE3546165A1 (de) | 1985-12-27 | 1985-12-27 | Verwendung von azoniaspironortropanolestern als asthmatherapeutikum und als broncholytikum |
| DE3546165 | 1985-12-27 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK626086D0 DK626086D0 (da) | 1986-12-23 |
| DK626086A DK626086A (da) | 1987-06-28 |
| DK168911B1 true DK168911B1 (da) | 1994-07-11 |
Family
ID=6289594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK626086A DK168911B1 (da) | 1985-12-27 | 1986-12-23 | Anvendelse af azoniaspironortropanolestere til fremstilling af et præparat til behandling af astma og bronchospasmer |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4780476A (enExample) |
| JP (1) | JPH0733334B2 (enExample) |
| DE (1) | DE3546165A1 (enExample) |
| DK (1) | DK168911B1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1265647B1 (it) * | 1992-11-18 | 1996-11-22 | Farmin Srl | Composizione farmaceutiche topiche per le allergie respiratorie |
| DE59600683D1 (de) * | 1996-11-27 | 1998-11-19 | Pfleger R Chem Fab | Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten |
| US7754242B2 (en) * | 2002-03-20 | 2010-07-13 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
-
1985
- 1985-12-27 DE DE19853546165 patent/DE3546165A1/de active Granted
-
1986
- 1986-12-23 US US06/945,773 patent/US4780476A/en not_active Expired - Lifetime
- 1986-12-23 DK DK626086A patent/DK168911B1/da not_active IP Right Cessation
- 1986-12-26 JP JP61308971A patent/JPH0733334B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK626086D0 (da) | 1986-12-23 |
| DE3546165C2 (enExample) | 1988-09-01 |
| US4780476A (en) | 1988-10-25 |
| DE3546165A1 (de) | 1987-10-15 |
| JPS62215525A (ja) | 1987-09-22 |
| DK626086A (da) | 1987-06-28 |
| JPH0733334B2 (ja) | 1995-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60113719T2 (de) | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten | |
| EP3581573B1 (en) | Synthesis of a compound that modulates kinases | |
| DE60015796T2 (de) | Neue aminopropylphosphinsäuren | |
| DE69815161T2 (de) | Azindolethylaminderivate als Nikotin-acetylcholin-Rezeptor Bindung Verbindungen | |
| DE2204195C2 (de) | 2-Hydroxymethyl-3-hydroxy 6-(1-hydroxy-2-aminoäthyl)-pyridine, Verfahren zu deren Herstellung und dieselben enthaltende pharmazeutische Zubereitungen | |
| MXPA04012271A (es) | Nuevos derivados de quinuclidina-amida. | |
| HU228594B1 (en) | Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same | |
| EP0353371A1 (en) | Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides | |
| AU9764298A (en) | Pharmaceutically available protoberberine salts derivatives, and protoberberine derivatives and salts thereof | |
| DK168911B1 (da) | Anvendelse af azoniaspironortropanolestere til fremstilling af et præparat til behandling af astma og bronchospasmer | |
| WO1998026779A1 (de) | Verwendung von 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen | |
| CN101490049A (zh) | 作为m3拮抗剂的奎宁环衍生物 | |
| MXPA04012272A (es) | Nuevos derivados de quinuclidina y composiciones medicinales que contienen los mismos. | |
| AU2241201A (en) | New (aminopropyl)methylphosphinic acids | |
| CH623830A5 (enExample) | ||
| DE2647041A1 (de) | 3-aminomethylen-6,7-dimethoxy-2- methyl-4-oxo-1,2,3,4-tetrahydro-1- chinolincarbonsaeureester und zwischenprodukte zur herstellung derselben | |
| DE69816633T2 (de) | Monozyklische verbingungen mit vier bifunktionellen resten und nk-2 antagonistischer aktivität | |
| DE3916803A1 (de) | Imidazolderivate und verfahren zu ihrer herstellung | |
| WO2011085389A1 (en) | Nicotinic acetylcholine receptor modulators | |
| DE2317183C2 (de) | Benzylamin-analgetika | |
| EP0770083A1 (de) | PYRIDO[3,2,1-i,j][3,1]BENZOXAZINDERIVATE | |
| DE969175C (de) | Verfahren zur Herstellung neuer therapeutisch wirksamer Benzhydrylaminoaethylaether | |
| DE2034139C (de) | 3 - Hydroxy-alpha-( 1 -aminoäthy T> benzylester und Arzneimittel | |
| JPH0637495B2 (ja) | アミノ置換された架橋アザビシクロキノロンカルボン酸およびエステル | |
| SU1319786A3 (ru) | Способ получени производных 2-диоксациклоалкилтиопенема в виде их солей с щелочными металлами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |